BioLineRx is trading at $2.70 (+5.65%) after its August 31, 2026 earnings release, as GLIX1 progress and financing may be outweighing weaker royalty revenue.
- Second-quarter revenue was $0.3 million, below the $0.5 million estimate.
- Active second-cohort dosing is underway, with third-cohort enrollment planned.
- A $3.75 million offering supports liquidity into the first half of 2027.